FindTrial
Sign In

Study for the safety and effectiveness of Wen-Yang Zhen-Shuai granule in treatment of chronic heart failure (Yang deficiency and water flooding syndrome)

Study for the safety and effectiveness of Wen-Yang Zhen-Shuai granule in treatment of chronic heart failure (Yang deficiency and water flooding syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025446
Enrollment
Unknown
Registered
2019-08-26
Start date
2019-08-27
Completion date
Unknown
Last updated
2019-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the chronic heart failure

Interventions

Control group:hydrochlorothiazide, enalaprilat, Metoprolol tartrate, Isosorbide mononitrate tablets
Experimental group:Wen-Yang Zhen-Shuai granules + hydrochlorothiazide, enalaprilat, Metoprolol tartrate, Isosorbide mononitrate tablets

Sponsors

The First Affiliated Hospital of Hu'nan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) According to the diagnostic criteria of chronic heart failure, the syndrome differentiation of TCM is Yang deficiency and water flooding syndrome; (2) Cardiac function in NYHA classification in II or III level, added the ACC/AHA classification C stage patients; (3) Aged 18 to 70 years; (4) Agree to participate in this study and sign the informed consent; (5) The primary disease is coronary heart disease and/or hypertension.

Exclusion criteria

Exclusion criteria: (1) Severe liver and renal insufficiency; (2) Nearly 3 months pregnant or lactating women; (3) Bilateral renal artery stenosis; (4) Combined with endocrine system, hematopoietic system and other serious primary diseases; (5) Allergic constitution or known allergy to the ingredients of this drug; (6) Low blood pressure; (7) Had fatal adverse reactions to ACEI, such as vascular edema and anuria renal failure; (8) Patients with poor compliance or abnormal mental state, do not cooperate with the examination and incomplete data; (10) Factors that increase mortality and uncontroled hypertension; (11) The patient participated in other clinical trials within three months; (12) The researchers judged the survival period to be less than three months; (13) The researcher judged that the patients could not complete the study or could not comply with the requirements of the study.

Design outcomes

Primary

MeasureTime frame
6 minute walk experiment;Myocardial enzyme spectrum;BNP;cardiac color ultrasound;electrocardiogram;chest film;—

Countries

China

Contacts

Public ContactJianhe Liu

The First Affiliated Hospital of Hu'nan University of Traditional Chinese Medicine

ljhtcm1@163.com+86 13975801090

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026